Table 3. Individual drugs used in patients with chronic heart failure (n=200) .
| Drug class | Drug | HFrEF (n=150) | HFpEF (n=38) | HFmrEF (n=12) |
| Diuretics |
Furosemide Torsemide Metolazone Indapamide Hydrochlorthiazide |
88 (58.6%) 28 (18.6%) 2 (1.3%) 4 (2.6%) 1 (0.6%) |
26 (68.4%) 8 (21%) 2 (5.2%) - 1 (2.6%) |
6 (50%) 4 (33.3%) - |
| MRAs |
Spironolactone Epleronone |
64 (42.6%) 10 (5%) |
22 (57.8%) 0 |
10 (83.3%) |
| ACEIs |
Enalapril Ramipril |
40 (26.6%) 30 (20%) |
9 (23.6%) 5 (13.1%) |
7 (58.3%) 5 (41.6%) |
| ARBs |
Losartan Telmisertan Olmesertan |
4 (2.6%) 8 (5.3%) 3 (2%) |
4(10.5%) - - |
2 (16.6%) |
| BBs |
Metoprolol Carvedilol Bisoprolol Nebivolol |
52 (34.6%) 18 (12%) 4 (2.6%) 2 (1.3%) |
- - - - |
|
| Glycosides | Digoxin | 40 (26.6%) | 2(5.2%) | 6 (50%) |
| Antithrombotics |
Aspirin Warfarin |
62(41.3%) 26 (17.3%) |
3 (7.8%) - |
5 (41.6%) |
| Inotropic agents | Dobutamine | 28 (14%) | - | |
| Dopamine | 22 (11%) | - | ||
| Noradrenaline | 6 (3%) | - | ||
| Nitrates |
GTN Isosorbide dinitrate |
8 (4%) 4 (2%) |
- - |
|
| Antiarrhythmics | Amiodarone | 10 (5%) | - |
Abbreviations: ACEIs, Angiotensin-converting enzyme inhibitors; ARBs, Angiotensin receptor blockers; BBs, Beta blockers; MRAs, Mineralocorticoid receptor antagonists; GTN, Glyceryl trinitrate; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFmrEF, heart failure with a mid-range ejection fraction.